Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis

作者：Taylor Hugh S^*

来源：Formulary, 2010, 45(2): 52-+.

Postmenopausal osteoporosis is a worldwide health concern associated with significant complications including fracture, disability, and mortality. The economic burden of this disease is substantial and is expected to increase significantly as the population ages. It is becoming increasingly important to identify patients who will benefit from available and emerging therapies for the prevention and/or treatment of osteoporosis. Although raloxifene is the only selective estrogen receptor modulator (SERM) currently approved for postmenopausal osteoporosis, several third-generation SERMs are undergoing clinical evaluation. Each investigational SERM has a unique clinical profile, with the overarching goal of developing an ideal SERM that provides the beneficial effects of estrogens without the associated risks and side effects. It is doubtful that any single SERM will have all of these characteristics, but novel SERMs such as bazedoxifene are likely to provide significant patient benefits that may translate to lower overall healthcare costs. (Formulary. 2010;45:52-61.)

• 出版日期2010-2